key: cord-0806368-atvq0i99 authors: Natarajan, A.; Shetty, A.; Delanerolle, G.; Zeng, Y.; Zhang, Y.; Raymont, V.; Rathod, S.; Halabi, S.; Elliot, K.; Phiri, P.; Shi, J. q. title: A systematic review and meta-analysis of Long COVID symptoms date: 2022-03-09 journal: nan DOI: 10.1101/2022.03.08.22272091 sha: 46bac308825780e6b4ed406e0a3c1df4c1692a0b doc_id: 806368 cord_uid: atvq0i99 Background Ongoing symptoms or the development of new symptoms following a SARS-CoV-2 diagnosis has caused a complex clinical problem known as Long COVID. This has introduced further pressure on global healthcare systems as there appears to be a need for ongoing clinical management of these patients. LC personifies heterogeneous symptoms at varying frequencies. The most complex symptoms appear to be driven by the neurology and neuropsychiatry spheres. Methods A systematic protocol was developed, peer reviewed and published in PROSPERO. The systematic review included publications from the 1st of December 2019 30th June 2021 published in English. Multiple electronic databases were used. The dataset has been analysed using a random-effects model and a subgroup analysis based on geographical location. Prevalence and 95% confidence intervals were established based on the data identified. Results Of the 302 studies, 49 met the inclusion criteria, although 36 studies were included in the meta-analysis. The 36 studies had a collective sample size of 11598 LC patients. 18 of the 36 studies were designed as cohorts and the remainder were cross-sectional. Symptoms of mental health, gastrointestinal, cardiopulmonary, neurological, and pain were reported. Conclusions The quality that differentiates this meta analysis is that they are cohort and cross-sectional studies with follow up. It is evident that there is limited knowledge available of LC and current clinical management strategies may be suboptimal as a result. Clinical practice improvements will require more comprehensive clinical research, enabling effective evidence-based approaches to better support patients. Therefore, a universally accepted Long COVID definition is yet to be elaborated, 124 although a general overview is available. One such important guideline set is from 125 the National Institute for Health and Care Excellence (NICE), which stipulates "Long 126 acute SARS-CoV-2 diagnosis post-4 weeks" (4). The current research landscape 128 exploring LC is also limited due to the varying reports of symptoms identified in 129 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint clinical datasets that demonstrates it to be a 'moving target' and it is challenging 130 clinical researchers to guide clinicians on the most optimal steps to pursue when reported symptoms that may influence neuropsychiatry and/or neurology and/or pain 153 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) A quality assessment was performed using the Newcastle-Ottawa Scale (NOS) 201 (Table 1a) to critically appraise the literature included within the systematic review 202 using common variables. Methodological quality and risk of bias was assessed by 203 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint independent reviewers according to the NOS, which has validity for use in cohort 204 studies (6) and the adapted version (7) for cross-sectional studies. The scale 205 consists of eight items with three quality parameters: (i) selection, (ii) comparability, 206 and (iii) outcome. We scored the quality of the studies (poor, fair, and good) by 207 allocating stars to each domain as stated below: 208 • A Poor quality score was allocated 0 or 1 star(s) in selection, 0 stars in 209 comparability, and 0 or 1 star(s) in the outcomes domain 210 • A Fair quality score was awarded, 2 stars in selection, 1 or 2 stars in 211 comparability, and 2 or 3 stars in outcomes. 212 • A Good quality score was awarded, 3 or 4 stars in selection, 1 or 2 in 213 comparability, and 2 or 3 stars in outcomes. (6) 214 [ Table 1a ] 216 217 A random-effects model with an inverse variance method was used for the meta-219 analysis and the heterogeneity was assessed by I 2 . A subgroup analysis was 220 conducted in terms of study geographical location on the symptoms that were 221 reported in more than 10 studies. Sensitivity analysis was used to test the 222 robustness of the results. Funnel plots and Egger's tests for symptoms with more 223 than 10 studies would be analyzed to detect publication bias. All data analysis will be 224 carried out using R and STATA 15. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint Of the 302 studies identified, 49 met the inclusion criteria. 36 studies were included 230 in the final meta-analysis. This was reported within the PRISMA document as 231 demonstrated in Figure 1 . The meta-analysis included 36 studies, which are summarized in Figure 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint General symptoms included those associated with pain (such as general pain, 256 muscle or joint pain, and mobility dysfunction), fatigue, fever, hair fall, skin rash, and 257 weight loss. The pooled prevalence of the general problem was 14.4% with a 95%CI 258 of 11.63% to 17.81%. A forest plot for general symptoms is shown in Figure 2 The pooled prevalence of joint pain and hair fall were 28.25% (95%CI 14.76% to 271 54.05%) and 20.29% (95%CI 10.56% to 38.98%) respectively. It appears that the 272 prevalence of these two symptoms were high, but only a few studies mentioned 273 these in comparison to those reporting fatigue and muscle pain. Therefore, it is worth 274 standardizing these variables across all studies to manage a better understanding of 275 the clinical relevance. 276 277 278 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint The neurological symptoms included headache, cognitive impairment, and loss of 280 smell, taste, and hearing. As shown in Figure 2 .2, the most frequently reported 281 neurological problems were loss of smell and taste, and headache. The pooled 282 prevalence for loss of smell or taste and both taste and smell as well as headaches 283 were 14.76%, 11.98%, 18.05%, and 10.45% respectively. However, the most 284 prevalent neurological symptom reported appears to be cognitive impairment with a 285 pooled prevalence of 28.85% with a 95%CI of 9.99% to 83.18%. The 95% CI is wide, 286 and the identified heterogeneity based on I 2 was 91%. Despite the high 287 heterogeneity, only 3 studies mentioned the symptoms of cognitive impairment. 288 Further studies and improved sampling would be required to demonstrate a more 289 precise statistical conclusion in regard to cognitive impairment and LC. Four symptoms, and mental health (MH) symptoms including depression, anxiety, 295 PTSD, and sleep disturbances, were reported within the neuropsychiatry category. 296 The pooled results can be found in Figure 2 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. with a 95%CI of 12.44% to 29.43%. This is an important facet to demonstrate given 304 that there is a large number of studies demonstrating depression and anxiety to be 305 the most commonly reported MH outcomes among SARS-CoV-2 patients. The overall prevalence of gastrointestinal problems, as shown in Figure 2 .5, was 322 6.22% with a 95%CI of 4.61% to 8.39% and is comparatively minimal to the other 323 categorical symptoms identified. Commonly reported symptoms reported in this 324 category were poor appetite, diarrhea and emesis, diarrhea or emesis, nausea, and 325 abdominal pain. Diarrhea and emesis had the highest prevalence of 14.64% with a 326 95%CI of 1.72% to 124.46%. Studies about diarrhea/emesis were too small. Only 327 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. was of concern to us. 10 studies from Europe reported dyspnoea in this subgroup 344 and the pooled prevalence of this subgroup was 30.87% with 95%CI of 20.18% to 345 41.55%, which was the second highest prevalence among different regions. This 346 suggested that dyspnoea was a highly prevalent symptom in European countries 347 and should be addressed by the healthcare system to improve post-discharge care. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint In Table 2 Table 3 , studies reporting symptoms of headache and dyspnea have 392 significant bias, with P-values of 0.022 and 0.007 respectively. Therefore, the pooled 393 prevalence of headache and dyspnea were 9.5% and 21.48%. In Figures 4(2) and 394 (3), the prevalence of headache and dyspnea may have been underestimated, and 395 more studies should be found to further confirm the conclusions. The population prevalence of long COVID identified here could be used to determine 432 symptom-based models to evaluate the requirement for healthcare system 433 resources, and possible disease sequalae which may require care. Presently, 434 instituting effective therapies is based upon present clinical knowledge than 435 evidence-based practices. Repurposing drugs is another common theme among 436 clinicians, and these raise concerns around long COVID potentially becoming a 437 chronic condition in the near future, especially for patients who had significant issues 438 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint with COVID. With a growing number of variants of SARS-Cov-2 virus, this further 439 exacerbates the present unknowns of managing these patients in an optimal 440 manner. However, this meta-analysis does provide an opportunity to plan early 441 intervention strategies and target therapies in the future. Similarly, sharing of data to better assess the mental and physical health sequalae 477 has been hampered by the lack of an international coordinating mechanism to do so 478 or a uniform set of guidelines that governments, public health officials, private 479 companies, and others may use to share such data. (14) As a result, COVID data 480 related to incidence, disease burden, and long COVID as well as a potential disease 481 sequalae may not be fully understood by the global healthcare community. This is a 482 particular a problem for assessing both COVID and long COVID syndrome impact on 483 A key finding of this study is that the speed at which SARS-CoV-2 research is being 500 conducted has meant epistemic authority consolidates around particular clinical 501 areas. Therefore, it is vital to synthesise the evidence without any background noise. 502 However, as demonstrated in this study, the gathering of LC data has been limited. 503 The identified data could be associated with autonomic dysfunction, although to 504 confirm this, further investigations would be required. Mapping LC outcomes would 505 be a long-term commitment; therefore, future systematic reviews and meta-analysis 506 should be reported in a living format, combining both clinical and research data to 507 allow a more comprehensive synthesis of evidence with a view to using surveillance 508 data. 509 510 511 512 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. This research is based on evidence gathered systematically and has not been 548 influenced unduly by expertise. 549 550 All other authors report no conflict of interest. 551 552 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint The views expressed are those of the authors and not necessarily those of the NHS, 553 the National Institute for Health Research, Department of Health and Social Care 554 or Academic institutions. 555 556 Funding 557 KE and GD are supported by National Institute for Health Research (NIHR) 558 Research Capability Funding (RCF) and by Southern Health NHS Foundation Trust. 559 All study sponsors had no further role in the study design, data collection, analysis, 560 and interpretation of data; in the writing of the report and in the decision to submit the 561 paper for publication 562 563 Authors' contributions 564 PP and GD developed study design and GD wrote the first draft of the manuscript. Acknowledgements 571 The . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. (1)Fatigue (2)Headache . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2022. 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint (2)Headache (3)Dyspnea (4) Cough . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (1)Fatigue (2)Headache . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2022. ; https://doi.org/10.1101/2022.03.08.22272091 doi: medRxiv preprint 3% Other Asian 6.8% Black British 7.6% Other black 13.9% Other ethnicity Marcel S. Woo 2020 cross-sectional study Tables 843 844 Table 1a